R ight ventricular (RV) function is a major determinant of functional capacity and survival in pulmonary arterial hypertension (PAH) and other types of pulmonary hypertension.
associated with a metabolic switch toward a more glycolytic state. 6 Recent studies in animals have proposed that suppressed angiogenesis, which would result in an imbalance between oxygen supply and delivery, could contribute to these phenomena, 7 potentially explaining why the hypertrophied RV muscle will fail. The hypoxia-inducible factor-1 (HIF-1)/vascular endothelial growth factor (VEGF) signaling pathways have been suggested as a critical regulator of angiogenesis, 8 although uncoupling between HIF-1 and VEGF expression has also been reported. 9 Thus, the mechanisms accounting for the decrease in angiogenesis in RV failure remain unclear.
Recent studies have demonstrated that microRNAs (miRNAs) are etiologically implicated in both PAH 10 and RV failure. 11 Interestingly, miR-126 is endothelium specific and a critical regulator of angiogenesis. 12 By repressing the Sprouty-related EVH1 domain-containing protein 1 (SPRED-1) and phosphatidylinositol-3-kinase regulatory subunit 2 (PIK3R2), two negative regulators of the VEGF signaling pathway, miR-126 activates both mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PIK3) signaling and promotes angiogenesis. [13] [14] [15] [16] We thus hypothesized that specific miR-126 downregulation would induce a SPRED-1-dependent inhibition of MAPK signaling pathways, decreasing angiogenesis and promoting the transition from a compensated RV hypertrophy (CRVH) to a decompensated RV hypertrophy (DRV) in PAH.
Using human hearts, we showed for the first time that RV failure in PAH is associated with miR-126 downregulation, accounting for decreased RV microvessel density and the transition from CRVH to DRV by decreasing angiogenesis via inhibition of the MAPK signaling pathway. In primary cultured endothelial cells (ECs) isolated from human patients with DRV, restoring miR-126 in vitro reverses the loss of angiogenesis, whereas in vivo injection of mimic-126 improves RV function in monocrotaline-induced PAH. Thus, this study proposes miR-126 as a novel RV-specific therapeutic target to treat RV failure in PAH.
Methods
All experiments were performed in accordance with Laval University and Institute Universitaire de Cardiologie et de Pneumologie de Québec biosafety and human (CER-20773) and animal (CER-2011-199-1) ethics. All patients or their legal representatives (in case of autopsy) gave informed consent before the beginning of the study. The online-only Data Supplement provides more details on all methods, including the supplies and chemicals used. All the experiments were performed with the use of an unbiased method: All the experiments were blindly performed and analyzed. Finally, a biostatistician performed and approved the statistics used in the present study.
Human Tissue Samples
Forty-one human RV tissues were obtained from autopsies (performed within 3 hours after death), heart transplantation, or cardiac surgery in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec site of the Respiratory Health Network tissue bank of the FRQS (www.tissuebank.ca). Tissue samples were categorized as normal RV (NRV), CRVH, or DRV on the basis of clinical history and the tricuspid annular plane systolic excursion (TAPSE) on cardiac echocardiography that closely correlates with RV ejection fraction 1 (Table and Table I in the online-only Data Supplement).
Animal Model
We used the same experimental model as that used in our previous study. 17 Briefly, male Sprague-Dawley rats (250 to 300 g; strain 400; Charles River) were selected for PAH induction with monocrotaline (60 mg/kg subcutaneous). Development of PAH was monitored noninvasively every week by echocardiography (Philips HD11 XE imaging system/S3-1 probe). Within 2 to 3 weeks after monocrotaline injection, RV and PA pressures had increased and RV hypertrophy was established. At that point, TAPSE and the S wave were slightly decreased, but stroke volume, cardiac output, and RV end-diastolic pressure were unchanged (CRVH stage). By the third to fourth week, the RV size was increased, along with RV end-diastolic pressure, whereas TAPSE, S wave, stroke volume, and cardiac output were significantly decreased, and obvious signs of heart failure (ie, ascites) and morbidity (ie, weight loss) were observable in the rats (DRV stage).
The following interventions were performed on the animals: Rats with established PAH (3 weeks after monocrotaline injection) were randomized to receive no treatment, 6 μg of in vivo-ready miR-126-5p mimic (Life Technologies, Burlington, ON, Canada), or miR-control (Life Technologies) prepared as previously described 18 and injected intravenously every 48 hours for 2 weeks. In a fourth treatment, to evaluate the tissue distribution, 6 μg fluorescent in vivo-ready miR-126-5p (Alexa Fluor 647-labeled in vivo-ready miR-126-5p mimic, Life Technologies) was injected intravenously every 48 hours for 2 weeks. At the end of the treatment period, echocardiography, exercise tolerance tests, and invasive closed-chest right heart catheterization (Transonic Scisense ADV500 Pressure-Volume Measurement System; analyzed with Labscibe2 software; Work System, Inc) were performed as previously described. Details on the methodology for these studies are given in the onlineonly Data Supplement. Note that RV cardiac fibrosis was quantified as previously described. Please note that some patients were taking >1 type of PAH medication, whereas 2 patients with PAH-pulmonary veno-occlusive disease were not receiving PAH-related medications (see Table I 
Statistical Analysis
Quantitative data are presented as mean±SEM. Variables were analyzed with 1-way ANOVA. One-way ANOVA was fitted to compare groups with heterogeneous variances and was tested to determine whether the model could be reduced to a 1-way analysis with the same variance across groups. When the effect that specifies heterogeneity in the covariance structure was significant (heteroscedasticity) compared with the same variance among groups, the statistical analyses were performed by use of separate residual variance per group. The Satterthwaite degree of freedom statement was added for unequal variance structures. The univariate of normality assumption was verified with Shapiro-Wilk tests on the error distribution by guest on April 18, 2017 http://circ.ahajournals.org/ Downloaded from from the statistical model. The Brown and Forsythe variation of the Levene test statistic was used to verify the homogeneity of variances. When appropriate, some variables were log-transformed to fulfill the model assumptions, and reported P values are based on these transformations. Adaptive tests using permutations of residuals were performed for data that did not fulfill the normality or variance assumptions after transformation or data with small sample sizes. When different conclusions between analyses from raw or transformed data and adaptive tests were reached, the latest approach was retained for statistical results. 
Results

RV Failure Is Associated With Decreased Capillary Density Independently of the VEGF/VEGF Receptor 2 Expression
The RV free wall of DRV displayed a significant decrease in capillary density measured by both CD31 + and Von Willebrand immunofluorescence compared with NRV and CRVH ( Figure 1A) , demonstrating that the transition from CRVH to RV failure is associated with a decrease in capillary density. Note that no differences were observed in the LV capillary . Interestingly, we found that the decrease in RV capillary density in DRV was not attributable to either a downregulation of VEGF/VEGF receptor-2 (VEGFR2) protein expression or a decrease in VEGFR2 activation (measured by phosphorylated VEGFR2 Y1054 and phosphorylated VEGFR2 Y1214 20 ; Figure 1B-1E ). This suggests that the decrease in RV angiogenesis is likely attributable to the modulation of the VEGF pathway downstream of the VEGFR2.
miR-126 Downregulation Accounts for the Decrease in Capillary Density in RV Failure
Because VEGF/VEGFR2 expression and activation were not affected in RV failure, we investigated whether the proangiogenic miR-126, which affects VEGF signaling downstream of the VEGFR2, 21 could contribute to the decrease in microvessel density in the DRV. Using quantitative reverse transcriptionpolymerase chain reaction, we showed that miR-126 expression is significantly decreased in DRV compared with NRV and CRVH (P<0.05) and correlates with TAPSE ( Figure 2A and Figure Figure IF in the online-only Data Supplement]). As expected, the downregulation of miR-126 expression in DRV was associated with a significant upregulation of SPRED-1 ( Figure 2B ), a direct target of miR-126 and a repressor of the VEGF pathway downstream of VEGFR2. 22 The biological efficacy of miR-126 downregulation was also confirmed by measuring the expression of the PI3KR2, a second direct target of miR-126 ( Figure 2C ). As expected both SPRED-1 and PI3KR2 expression negatively correlated with miR-126 expression ( Figure IG and IH in the online-only Data Supplement). SPRED1 decreases angiogenesis by negatively regulating the activation of the MAPK pathway via the binding and inactivation of RAF, an upstream kinase of the pathway. Therefore, we measured both RAF (phosphorylated RAF/RAF) and ERK (phosphorylated ERK/ERK) activation using immunoblots. As expected, the last 2 effectors of the VEGF/MAPK pathway were significantly decreased in DRV compared with CRVH ( Figure 2D and 2E). These results suggest that the angiogenic impairment observed in PAH-associated RV failure is attributable to an alteration of the VEGF/VEGFR2/MAPK pathway, subsequent to the downregulation of miR-126 and the upregulation of the protein SPRED-1.
Overexpression of miR-126 In Vitro Restores the Angiogenic Potential of ECs Isolated From Human DRV Patients
First, we confirmed that miR-126 expression was also significantly decreased in human ECs (positive for CD31; Figure  IIA in the online-only Data Supplement) isolated from DRV compared with human ECs isolated from CRVH and NRV ( Figure 3A) . Using Matrigel assays, we showed that ECs isolated from human CRVH displayed increased angiogenic potential compared with NRV. Conversely, the angiogenic capacity of ECs from DRV was markedly decreased compared with both NRV and CRVH ( Figure 3B ). These findings were associated with a significant decrease in the proliferation rate (Ki67 assay) and an increase in the apoptosis rate (annexin V assay) of ECs isolated from DRV compared with ECs from CRVH ( Figure 4C and 4D). We next confirmed the implication of miR-126 on the angiogenic potential of RV ECs. 23 efficacy of the transfection of both miR-126 antagomir/mimic and siSPRED-1 in primary cultured human ECs has been recently published by our group. 12 We then attempted to identify the mechanism responsible for miR-126 downregulation in DRV ECs. We performed several stimulation experiments and found that miR-126 expression is not downregulated by hypoxia, tumor necrosis factor, or interleukin-6 ( Figure IIIA and IIIB in the onlineonly Data Supplement), well-known triggers involved in the pathogenesis of PAH and RV failure. 24, 25 E26 transformation-specific sequence-1/2 transcription factors have been implicated in the regulation of miR-126 expression 26 but were unchanged between CRV and DRV ( Figure IIIC in the online-only Data Supplement). Recent studies revealed a large CpG island upstream from the miR-126 transcriptional site in the EGFL7 gene (miR-126 host gene). Moreover, miR-126 has previously been shown to be upregulated in cancer cell lines treated with inhibitors of DNA methylation, 27 suggesting that epigenetic regulation could directly affect miR-126 expression. Interestingly, methylation has been implicated in PAH pathogenesis 28 with the upregulation of DNA methyl transferase (DNMT). 29 Thus, DRV ECs were treated with hydralazine (a DNMT inhibitor 30 ). Hydralazine dose-dependently increased miR-126 in DRV ECs ( Figure  IIID in the online-only Data Supplement). In addition, we showed that DRV, which exhibited a low expression level of miR-126, had highly methylated promoters compared with CRVH, which expressed higher levels of miR-126 ( Figure  IIIE in the online-only Data Supplement). Interestingly, the changes seen in methylation levels were associated with an upregulation of DNMT3a and DNMT3b expression in DRV compared with CRVH ( Figure IIIF and IIIG in the onlineonly Data Supplement).
Systemic miR-126 Upregulation Improves RV Function in Monocrotaline Rats
In a manner similar to DRV patients, monocrotaline rats at the DRV stage also had an important attenuation of miR-126 expression, resulting in SPRED-1 upregulation and a decrease in microvessel density (percent of CD31 + cells) compared We then assessed the role of miR-126 in RV failure using a bidirectional approach by testing whether miR-126 upregulation (mimic-126) can prevent RV failure and by determining whether miR-126 downregulation can induce it. To verify the efficacy of our intervention, we performed 3 sets of experiments. We showed (1) Figure 6C and 6D) , confirming a role for miR-126 in RV failure pathogenesis in our rat model. To further demonstrate the efficacy of our treatment on RV function, invasive hemodynamic measurements were performed. We observed that animals treated with the mimic-126 displayed a significant decrease in RV end-diastolic pressure and an increase in cardiac output and stroke volume associated with a decrease in RV end-systolic volume, whereas RV end-diastolic volume was unchanged ( Figure 6E-6I) . Finally, improvement in RV function was associated with an increase in exercise capacity ( Figure 6J ). In an opposing manner, antagomiR-126-treated rats had increased RV end-diastolic pressure and decreased cardiac output and stroke volume compared with the antagomiR control-treated rats ( Figure 5C-5F ). Importantly, no changes in RV systolic pressure, mean PA pressure, RV hypertrophy (RV/LV + septum ratio), and medial thickness of small and medium-sized PAs ( Figure 7A-7D) were observed, suggesting that the effects of miR-126 on RV function were probably not attributable to modulation in pulmonary afterload. Finally, miR-126 mimic-treated animals had decreased SPRED-1 expression ( Figure IVA in the online-only Data Supplement), resulting in a significant increase in RV capillary density (CD31 staining, Figure 5B ). As expected, antagomiR-126-treated rats had increased SPRED-1 ( Figure VIH in the online-only Data Supplement) and decreased RV capillary density ( Figure VI , part I in the online-only Data Supplement). Interestingly, recent studies documented that miR-126 overexpression downregulates the mRNA levels of the fibrotic marker α-smooth muscle actin. 31 We thus explored the impact of miR-126 modulation on RV fibrosis and confirmed that mimic-126 injections were also associated with decreased RV fibrosis, whereas antagomiR treatment was associated with increased fibrosis (Masson trichrome; Figure 7E and Figure  VIJ in the online-only Data Supplement). Note that miR-126 upregulation did not affect VEGF or VEGFR2 expression (data not shown). Thus, we identified RV miR-126 expression as a central mediator of RV failure in PAH; a schematic representation of our hypothesis is presented in Figure 8 . 
Discussion
The present study demonstrates a role for miR-126 in RV failure observed in PAH patients. It also provides extensive mechanisms linking the methylation-dependent downregulation of miR-126 to decreased angiogenesis and capillary rarefaction within the RV of PAH patients. More important, in vivo experiments showed that miR-126 upregulation restores RV microvascular density and improves RV function and fibrosis, whereas miR-126 downregulation exacerbates RV failure. Thus, our study demonstrates the importance of miR-126 as a new therapeutic target for RV failure in human PAH.
Abnormal miRNA expression has been shown in experimental RV failure. 11 Indeed, other studies have reported miRNA changes in RV hypertrophy models. For example, miR-34 and miR-21 were found to be downregulated and miR-1 upregulated in the PA-banding model. 31 Downregulation of miR-1 and miR-133 was also observed in the PA-banding model 32 compared with the Sugen/hypoxia model. 33 Nonetheless, the role of these miRNAs in the pathogenesis of RV failure is unknown. Finally, we recently reported that the cardiomyocyte-specific miRNA miR-208 was downregulated in the same monocrotaline rat model as the one used in the present study, 34 contributing to the adverse RV remodeling. Nevertheless, the role for miRNAs in human RV failure has never been explored. Thus, the present study provides the first evidence for their implications in the pathogenesis of RV failure in human PAH.
Survival in PAH is closely related to RV function. 35 Although pulmonary load is an important determinant of RV Invasive catheterization of the right side of the heart in closed chest was performed for hemodynamic measurements. RV end-diastolic pressure (RVEDP; E), cardiac output (CO; F), and stroke volume (SV; G) were decreased in monocrotaline (n=5) compared with control (n=9) rats, whereas DRV rats treated with mimic-126 (n=5) displayed a significant increase in CO compared with DRV+vehicle rats (n=5). End-systolic volume (ESV; H and (I) end-diastolic volume (EDV; I) also increased in DRV and DRV+vehicle rats (n=5 and 6) compared with control rats (n=6), but only ESV was decreased by miR-126 treatment (n=5) compared with vehicle-treated DRV rats (n=6). J, Exercise tolerance decreased in DRV rats (n=6) compared with controls (n=11) and significantly improved in rats treated with mimic-126 (n=4) compared with DRV+vehicle (n=5 systolic function in PAH, RV adaptation to this increased afterload depends not only on the severity of pulmonary vascular disease but also on changes in myocardial metabolism, rate of myocardial hypertrophy and fibrosis, and adaptation of the capillary network. 36 This complex interplay likely explains the significant variability in RV adaptation to PAH between patients.
In keeping with several previous studies in RV failure, 8, 37 our study showed that, as in experimental PAH, 8, 9 human RV failure is associated with decreased capillary density ( Figure 1A) . Recently, Sutendra et al 8 proposed that, in the monocrotaline-induced PAH rat model, CRVH is characterized by a metabolic switch from oxidative phosphorylation to a glycolytic state, allowing the activation of HIF-1, increasing VEGF expression, and preserving angiogenesis. On entrance to RV failure, the loss of this metabolic phenotype resulted in a decrease in HIF-1 and thus an insufficient production of VEGF, inducing capillary rarefaction. Nonetheless, De Raaf et al 38 showed in the Sugen-induced PAH rat model that the decrease in VEGF seen in the RV can occur independently of HIF-1 expression. Although both studies revealed a decrease in VEGF, the expression pattern of the receptor or its activity was not assessed. Thus, VEGF-independent mechanisms cannot be ruled out. This is in keeping with a human study showing that VEGF restoration therapy in human LV failure was unsuccessful, despite promising animal studies. 39 These findings suggests that, in addition to existing metabolic/HIF-1/ VEGF signaling pathways described in rodents, other molecular mechanisms are likely implicated in capillary rarefaction seen in human heart failure. In fact, we provide evidence in human RVs that the decrease in angiogenesis does not exclusively rely on changes in VEGF and VEGFR2 expression/activation ( Figure 1B-1E ) but also relies on the downregulation of miR-126 ( Figure 2A) . Interestingly, a recent study performed in mesothelioma provided evidence that miR-126 is downregulated under a glycolytic environment, 40 which is in keeping with the Sutendra et al 8 theory described above. Nonetheless, neither hypoxia nor inflammation, both implicated in PAH metabolic changes, 24, 25 induces miR-126 downregulation in CRVH ECs ( Figure IIIA and IIIB in the online-only Data Supplement). Until recently, the mechanisms accounting for miR-126 regulation remained unknown. The transcription factors E26 transformation-specific sequence-1 and -2, implicated in controlling miR-126 expression, were unchanged 24 in CRVH compared with DRV ( Figure IIIC in the online-only Data Supplement). Although the beneficial effects of hydralazine as a vasodilator are attributed to K + channel opening in ECs, 41 other potential effects include DNMT inhibition 30 and thus DNA methylation, which is known to regulate miR-126 expression. 42 Even if the effects of hydralazine on DNA Figure IIID -IIIG in the online-only Data Supplement). Thus, by inhibiting DNMT, hydralazine contributes to the upregulation of miR-126 and thus angiogenesis, confirming previous findings and providing a proangiogenic effect of hydralazine in cardiovascular diseases. 43 This could explain the increase in cardiac output observed in patients with PAH treated with hydralazine. 44 Among the angiomiRs, miR-126 has unique properties that makes it an attractive therapeutic target. It is expressed predominantly in ECs and has been shown to regulate vascular integrity and developmental angiogenesis. 21 The proangiogenic effect of miR-126 has been attributed, at least in part, to the repression of SPRED-1, a negative regulator of the VEGF signaling pathway, which results in the activation of MAPK signaling in response to VEGF. 13 In the present study, using primary cultured human ECs isolated from RV tissues, we demonstrated the ability to recreate a DRV angiogenic phenotype in ECs isolated from CRVH by abating miR-126 levels and the capacity to restore a normal angiogenic phenotype in ECs isolated from DRV through artificial overexpression of miR-126 or inhibition of SPRED-1 ( Figure 4B and Figure IID in the online-only Data Supplement). These findings confirm the key role of miR-126 in angiogenic impairment associated with RV failure in human PAH. Furthermore, although preservation of the RV microcirculation in vivo through intravenous miR-126 injection was associated with maintained RV function in monocrotaline-induced PAH ( Figure 6A-6I) , we also demonstrated that the downregulation of miR-126 exacerbates RV failure in monocrotaline rats in their CRVH stage. Although our data suggest that miR-126-dependent improvement in RV function appeared to be related primarily to increases in RV capillary density, a decrease in pulmonary afterload cannot be totally excluded because impaired angiogenesis and markedly reduced miR-126 expression in concentric lesions of remodeled PAs have been shown in the lungs of PAH patients. 45 Nonetheless, our injections of miR-126 did not affect miR-126 levels in the lungs, and no histological change in PA remodeling was observed ( Figure 7A-7D ). In addition, indirect effects of miR-126 on RV fibrosis ( Figure 7E ) also could have contributed to improved RV function in miR-126-treated rats. 46 Moreover, miR-126 might contribute to cardiac regeneration by influencing cardiac repair through affecting the homing ability of circulating hematopoietic progenitor cells, which might contribute to cardiac regeneration.
Recent advances in PAH therapeutics have improved patients' symptoms and quality of life. However, RV failure remains the first cause of death in PAH, and there are no therapies currently available that directly target the RV function. 36 Nonetheless, several drugs are under clinical development for the treatment of hypertrophic cardiomyopathy and heart failure such as histone deacetylase (HDAC) inhibitors. Interestingly, a recent study demonstrated that the protective effects of HDAC inhibitors on cardiac myocytes was due, at least in part, to the upregulation of miR-126, 47 supporting a beneficial role for miR-126 in heart failure. It should be noted, however, that the use of HDAC inhibitors for RV failure is controversial; some studies suggested a beneficial effect of HDAC inhibitors on RV function in PAH, 48 while another showed that HDAC inhibition worsened RV function in a PA-banding rat model (a model of CRVH). 49 Taken together, these studies suggest that the use of HDAC inhibitors may be beneficial in DRV (when miR-126 is decreased), whereas its inhibition may be detrimental when miR-126 is preserved. Intriguingly, miR-126 upregulation improved RV function and fibrosis when miR-126 was initiated in a late CRVH stage in the present study, suggesting that deleterious effects of HDAC inhibitors are likely to be miR-126 independent.
Our study has several limitations. First, despite using an in vivo closed-chest pressure-volume loop system to assess RV function, we were not able to evaluate the ratio of end-systolic elastance and arterial elastance even by the single-beat method. Thus, one could consider that our evaluation of the RV function is suboptimal and that part of the improvement in RV function could be related to decreases in pulmonary vascular load. 50 Indeed, although PA remodeling and lung miR-126 expression remained unchanged after miR-126 upregulation, enhanced angiogenesis within the pulmonary circulation could not be totally excluded. The use of only the monocrotaline rat model could be seen as a second limitation. We certainly acknowledge that other models exist. However, because the development of PAH and RV failure in the Sugen/hypoxia model is attributable to VEGF inhibition, we thought that its use was not appropriate to study the angiogenesis signaling network.
Finally, miRNA-based therapy in animals has shown promising results in both PAH and heart disease. 11, 12 More recently, clinical trials showed that miRNA-based therapies could be safe and effective in humans. 51 We thus believe that, in addition to providing a better understanding of the molecular factors contributing to the transition from CRVH to DRV in PAH, our study opens the door to new avenues of investigation and potentially future RV-specific therapies in PAH. Masson's trichrome staining was performed to grade myocardial fibrosis as previously published 1 . Also, PA remodelling was measured using hematoxylin and eosin staining as previously described 2 .
qRT-PCR and immunoblotting analysis. Figure S2A and S2B in the online supplement. For each experiment, we used a proper control (mimics or hairpin inhibitor negative control #1 from Thermo Fisher Scientific, Asheville, NC). The assay plate was incubated for 48 hours at 37°C, 5% CO 2
atmosphere. For each condition, pictures were taken using phase contrast microscopy and branch points were blindly counted to quantify angiogenic capacity of cells.
Proliferation and apoptosis measurements. To study the in vitro effect of miR-126 on human RV ECs' proliferation and apoptosis, cultured CD31 + cells isolated from human NRV and DRV were exposed to EBM-2 media (Lonza) with growth factor supplementation (ECs Growth Media Kits) for 48h to assess proliferation, or EBM-2 media (Lonza) without supplementation (serum and growth factor starvation for 48h) to assess apopotosis. Proliferation was measured using Ki67 assay (EMD Millipore) and apoptosis by AnnexinV assay (Clontech, Mountai view, CA). Briefly, 3 independent sets of experiments were performed in CD31 + cells from control subjects and idiopathic PAH patients. In each experiment, a minimum of 45 cells was evaluated.
Animals intervention.
At the time of monocrotaline (MCT) injection, rats were randomized to receive 1) no treatment (control); 2) Anti-hsa-miR-126-5p miScript Furthermore, non-parametric tests were performed and results were very similar to results from adaptive tests with no change in statistical conclusion.
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